EVP, Pres., Novocure Oncology
Avg Cost/Share
$18.07
Shares
30,196
Total Value
$528,412.59
Owned After
176,931
EVP, Pres., Novocure Oncology
Avg Cost/Share
$18.54
Shares
2,527
Total Value
$46,841.23
Owned After
176,931
SEC Form 4
EVP, Pres., Novocure Oncology
Avg Cost/Share
$19.59
Shares
30,072
Total Value
$592,513.68
Owned After
176,931
EVP, Pres., Novocure Oncology
Avg Cost/Share
$15.94
Shares
598
Total Value
$9,530.74
Owned After
176,931
SEC Form 4
EVP, Pres., Novocure Oncology
Avg Cost/Share
$16.02
Shares
2,519
Total Value
$40,357.57
Owned After
176,931
EVP, Pres., Novocure Oncology
Avg Cost/Share
$16.14
Shares
2,078
Total Value
$33,544.74
Owned After
176,931
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Leonard Frank X | NVCR | EVP, Pres., Novocure Oncology | Jun 2, 2025 | Sell | $18.07 | 30,196 | $528,412.59 | 176,931 | |
| Leonard Frank X | NVCR | EVP, Pres., Novocure Oncology | Mar 3, 2025 | Sell | $18.54 | 2,527 | $46,841.23 | 176,931 | |
| Leonard Frank X | NVCR | EVP, Pres., Novocure Oncology | Feb 27, 2025 | Sell | $19.59 | 30,072 | $592,513.68 | 176,931 | |
| Leonard Frank X | NVCR | EVP, Pres., Novocure Oncology | Nov 1, 2024 | Sell | $15.94 | 598 | $9,530.74 | 176,931 | |
| Leonard Frank X | NVCR | EVP, Pres., Novocure Oncology | Mar 1, 2024 | Sell | $16.02 | 2,519 | $40,357.57 | 176,931 | |
| Leonard Frank X | NVCR | EVP, Pres., Novocure Oncology | Feb 27, 2024 | Sell | $16.14 | 2,078 | $33,544.74 | 176,931 |